Updates are available Correction dated 2026-03-05
Click to view Correction: https://doi.org/10.1007/s00210-025-04898-y
-
Authors
Wu, Chao
Li, Ying
Chen, Shuxing
Wang, Liuning
Chen, Bangjie
Zhang, Fenglin
Zhang, Ziran
Zhang, Congjun
-
Funding
Funding for this research was provided by:
Huilan Public Welfare-Haosen Pharmaceutical Lung Cancer Precision Medicine Research Special Fund - Real World Study on Amatitinib Treatment for EGFRm NSCLC (HL-HS2020-21)
- License Information
-
More Information
Article History
Received: 22 May 2025
Accepted: 13 August 2025
First Online: 4 October 2025
Change Date: 4 March 2026
Change Type: Update
Change Details: The original online version of this article was revised: The institutions of Chao Wu and Ziran Zhang are incorrect.
Change Date: 5 March 2026
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s00210-025-04898-y
Declarations
:
: This study was approved by the Medical Ethics Committee of the First Clinical Medical College (First Affiliated Hospital) (PJ2023-08–35).
: Not applicable.
: The authors declare no competing interests.
